Navigation Links
Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
Date:2/10/2011

ed in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
3. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
5. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
7. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
8. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
9. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
10. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
11. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DALLAS , April 17, 2015 ... report 2015 Market Research Report on Global and ... This is a professional and the deep ... the report introduces Lysine basic information including definition, ... overview (such as US, Europe ...
(Date:4/17/2015)... R.I , April 17, 2015 CVS ... a conference call on Friday, May 1, 2015, at ... its first quarter financial results. An audio ... through the Investor Relations portion of the CVS Health ... visit http://investors.cvshealth.com . This webcast will be archived ...
(Date:4/17/2015)... SAN DIEGO , April 17, 2015 /PRNewswire/ ... molecular diagnostics, announced today that clinical data presented ... demonstrate that its urine-based Precision Cancer Monitoring ℠ ... detection and monitoring of EGFR T790M ... titled Detection of EGFR T790M Mutation in ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... The ALS Therapy Development Institute (ALS ... with Neurotune to investigate a potential treatment ... (Photo: http://photos.prnewswire.com/prnh/20120514/DC05793 ) ... health of motor neurons and their connections to muscles ...
... 2012  NxStage® Medical, Inc. (Nasdaq: NXTM ... today announced that former NxStage® System One™ patient ... transplant following four successful years of more frequent ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) The ...
Cached Medicine Technology:The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant 2Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant 3
(Date:4/18/2015)... 2015 Carinsurancesavings.biz has released a new ... are cheaper during Spring. , Spring can be ... Drivers should make sure they compare the newest policies ... can learn more about Spring car insurance offers by ... insurance quotes are becoming more and more popular. Many ...
(Date:4/18/2015)... SMITHTOWN, NEW YORK (PRWEB) April 18, 2015 ... Inc. (AMO) are hosting a ‘Strategies for Success’ program ... & Refractive Surgeons meeting in San Diego, where eye ... ‘Distinguished Moderator’ for this invitation-only event. Dr. Martin is ... AMO and Review of Ophthalmology chose Dr. Martin to ...
(Date:4/18/2015)... Patients who undergo radiation for a hematologic ... life, but the disease is likely to differ in ... radiation. Surviving Mesothelioma has just posted the details of ... to read it now. , Scientists from China, ... patients who had both a hematologic cancer (like lymphoma ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released Volume ... say, “exposes a tactical shift by cyberattackers.” With everything from ... in 2014 - almost a million a day - to ... identified and patched by prominent manufacturers – as long as ... in a digital world can be fraught with peril, and ...
(Date:4/18/2015)... 2015 French physician and gastronome Anthelme ... when he uttered, “Tell me what you eat, and ... to cope with stress or sadness has often been ... indicates otherwise. Data collected from their Emotional Eating ... emotional eating, but for different reasons. , Collecting data ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... given the same procedure by an average of 4.5 years, ... ,And while younger people tend to live longest of ... life compared with those who have not had liver transplants, ... life expectancy and years of life lost of 2702 people ...
... performed by physicians experienced with the technique//, and pain ... one-year, multi-center cohort study. ,Among the 25 patients ... on a 10-point visual analog scale was 7.3 at ... at 24 weeks, and 0.3 at 52 weeks, according ...
... for treating patients with advanced colorectal cancer has been approved ... other parts of the body.//Panitumamab, which is being marketed as ... size and retard cancer cell growth. ,The approval has ... which has a high mortality rate. Colorectal cancer has been ...
... women after consumption of raw oysters. Further probing revealed that ... ,Agriculture Commissioner Tommy Irvin commenting on the deaths said “The ... and they lost their lives.” In his opinion, raw oysters ... DeKalb Farmers’ Market reiterated that they have always been enabling ...
... Recent studies conducted by Yale School Of Medicine have ... androgens or steroids to enhance muscle mass or for ... in the body can lead to a appalling loss ... steroids was previously proven to cause hyper excitability, volatile ...
... is the most notorious of cancers, going by the United Kingdom ... of three cases happens to be of the breast. , ... increase in cancer. The present record for breast cancer is 36,939 ... cancer is up since 1971 by almost 81%. ...
Cached Medicine News:Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 3Health News:FDA Approves Vectibix for Colorectal Cancer 2
Each blade is perfectly crafted to enhance your performance, expertise and safety. You are always assured of a uniform cutting edge and a perfect fit on scalpel handles with every procedure....
RM-1900 Dermatome developed for reconstructive plastic surgery with E-Type coupling. Dermatome with 50 mm cutting width....
Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....
Bagolini's striated lenses consists of 2 circular lenses in a metal frame with tabs for use by the examiner....
Medicine Products: